Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications
Authors:
- Hendrien KuipersHKHendrien Kuipers
- Tessa J. J. de BitterTBTessa J. J. de Bitter
- Marieke T. de BoerMBMarieke T. de Boer
- Rachel S. van der PostRPRachel S. van der Post
- Maarten W. NijkampMNMaarten W. Nijkamp
- Philip R. de ReuverPRPhilip R. de Reuver
- Rudolf S. N. FehrmannRFRudolf S. N. Fehrmann
- Frederik J. H. HoogwaterFHFrederik J. H. Hoogwater
Open Access
Abstract
Due to the fast progression in molecular technologies such as next-generation sequencing, knowledge of genetic alterations in gallbladder cancer (GBC) increases. This systematic review provides an overview of frequently occurring genetic alterations occurring in GBC and their possible therapeutic implications. A literature search was performed utilizing PubMed, EMBASE, Cochrane Library, and Web of Science. Only studies reporting genetic alterations in human GBC were included. In total, data were extracted from 62 articles, describing a total of 3893 GBC samples. Frequently detected genetic alterations (>5% in >5 samples across all studies) in GBC for which targeted therapies are available in other cancer types included mutations in ATM, ERBB2, and PIK3CA, and ERBB2 amplifications. High tumor mutational burden (TMB-H) and microsatellite instability (MSI-H) were infrequently observed in GBC (1.7% and 3.5%, respectively). For solid cancers with TMB-H or MSI-H pembrolizumab is FDA-approved and shows an objective response rates of 50% for TMB-H GBC and 41% for MSI-H biliary tract cancer. Only nine clinical trials evaluated targeted therapies in GBC directed at frequently altered genes (ERBB2, ARID1A, ATM, and KRAS). This underlines the challenges to perform such clinical trials in this rare, heterogeneous cancer type and emphasizes the need for multicenter clinical trials.Keywords
This publication has 115 references indexed in Scilit:
- Epidemiology of Gallbladder Disease: Cholelithiasis and CancerGut and Liver, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor GenotypingThe Oncologist, 2011
- Mutational profiling reveals PIK3CA mutations in gallbladder carcinomaBMC Cancer, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Obesity and the risk of gallbladder cancer: a meta-analysisBritish Journal of Cancer, 2007
- Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladderJournal of Gastroenterology, 2005
- Epidemiology and Molecular Pathology of Gallbladder CancerCA: A Cancer Journal for Clinicians, 2001